The role of iron in pulmonary pathology

Multidisciplinary Respiratory Medicine

Volumn 10, Issue 1, 2015, Pages

  Khiroya, Heena ^a,b   Turner, Alice M ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

ARDS; Cancer; Cigarette; COPD; Infection; IREB2; Iron

Indexed keywords

CIGARETTE SMOKE; INTERLEUKIN 8; IRON; IRON REGULATORY PROTEIN 2;

ADULT RESPIRATORY DISTRESS SYNDROME; CHRNA3 GENE; CHRNA5 GENE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE RELEASE; EMPHYSEMA; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HOMEOSTASIS; HUMAN; INFECTION SENSITIVITY; IREB2 GENE; IRON BALANCE; IRON CHELATION; IRON HOMEOSTASIS; IRON METABOLISM; LUNG CANCER; LUNG CARCINOGENESIS; LUNG DISEASE; LUNG INFECTION; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PHENOTYPIC VARIATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

EID: 84951905276     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/s40248-015-0031-2     Document Type: Review

References (73)

1. Hubbard R. The burden of lung disease. Thorax. 2006; 61(7):557-8.
2. Morgan JW, Anders E. Chemical-composition of earth, venus, and mercury. Proc Natl Acad Sci U S A. 1980; 77(12):6973-7.
3. Ghio AJ, Hilborn ED, Stonehuerner J.G., Dailey LA, Carter JD, Richards JH, et al Particulate matter in cigarette smoke alters iron homeostasis to produce a biological effect. Am J Respir Crit Care Med. 2008; 178(11):1130-8.
4. Ghio AJ. Disruption of iron homeostasis and lung disease. Biochim Biophys Acta. 2009; 1790(7):731-9.
5. Hardin M, Zielinski J, Wan E.S., Hersh CP, Castaldi PJ, Scwinder E, et al CHRNA3/5, IREB2, and ADCY2 are associated with severe chronic obstructive pulmonary disease in Poland. Am J Respir Cell Mol Biol. 2012; 47(2):203-8.
6. Walling C, Partch RE, Weil T. Kinetics of the decomposition of hydrogen peroxide catalyzed by ferric ethylenediaminetetraacetate complex. Proc Natl Acad Sci U S A. 1975; 72:140-42.
7. Park CH, Bacon BR, Brittenham G.M., Tavill AS. Pathology of dietary carbonyl iron overload in rats. Lab Invest. 1987; 57:555-63.
8. Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol. 2004; 11(4):251-4.
9. Hentze MW, Muckenthaler MU, Andrews NC Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004; 117(3):285-97.
10. Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat Rev Immunol. 2015; 15(8):500-10.
11. Aisen P. Transferrin, the transferrin receptor, and the uptake of iron by cells. Met Ions Biol Syst. 1998; 35:585-631.
12. Aisen P. Transferrin receptor 1. Int J Biochem Cell Biol. 2004; 36(11):2137-43.
13. Silva B, Faustino P. An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochim Biophys Acta. 2015; 1852(7):1347-59.
14. Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Curr Top Cell Regul. 1997; 35:1-19.
15. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol. 2006; 2(8):406-14.
16. LaVaute T, Smith S, Cooperman S., Iwai K, Land W, Meyron-Holtz E, et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet. 2001; 27(2):209-14.
17. Galy B, Ferring D, Minana B., Bel O, Janser HG, Muckenthaler M, et al Altered body iron distribution and microcytosis in mice deficient in iron regulatory protein 2 (IRP2). Blood. 2005; 106(7):2580-9.
18. Meyron-Holtz E.G., Ghosh MC, Iwai K, LaVaute T., Brazzolotto X, Berger UV, et al Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis. EMBO J. 2004; 23(2):386-95.
19. Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Mechanisms of mammalian iron homeostasis. Biochemistry. 2012; 51(29):5705-24.
20. Guo B, Phillips JD, Yu Y, Leibold EA Iron regulates the intracellular degradation of iron regulatory protein 2 by the proteasome. J Biol Chem. 1995; 270(37):21645-51.
21. Chepelev NL, Willmore WG Regulation of iron pathways in response to hypoxia. Free Radic Biol Med. 2011; 50(6):645-66.
22. Hanson ES, Foot LM, Leibold EA Hypoxia post-translationally activates iron-regulatory protein 2. J Biol Chem. 1999; 274(8):5047-52.
23. Kirschner RE, Fantini GA Role of iron and oxygen-derived free radicals in ischemia-reperfusion injury. J Am Coll Surg. 1994; 179(1):103-17.
24. Guo RF, Ward PA Mediators and regulation of neutrophil accumulation in inflammatory responses in lung: Insights from the IgG immune complex model. Free Radical Biol Med. 2002; 33(3):303-10.
25. Nelson ME, O'Brien-Ladner AR, Wesselius LJ. Regional variation in iron and ironbinding proteins within the lungs of smokers. Am J Respir Crit Care Med. 1996; 153(4 Pt 1):1353-8.
26. O'Brien-Ladner AR, Nelson SR, Murphy WJ, Blumer BM, Wesselius LJ. Iron is a regulatory component of human IL-1beta production. Support for regional variability in the lung. Am J Respir Cell Mol Biol. 2000; 23(1):112-9.
27. Pateva IB, Kerling EH, Reddy M, Chen D., Carlson SE, Tancabelic J. Effect of maternal cigarette smoking on newborn iron stores. Clin Res Trials. 2015; 1(1):4-7.
28. Ghio AJ, Pritchard RJ, Dittrich K.L., Samet JM. Non-heme (Fe3+) in the lung increases with age in both humans and rats. J Lab Clin Med. 1997; 129(1):53-61.
29. Rubenfeld GD, Caldwell E, Peabody E., Weaver J, Martin DP, Neff M, et al Incidence and outcomes of acute lung injury. N Engl J Med. 2005; 353(16):1685-93.
30. DeMeo DL, Mariani T, Bhattacharya S., Srisuma S, lange C, Litonjua A., et al. Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet. 2009; 85(4):493-502.
31. Chappell SL, Daly L, Lotya J., Alsaegh A, Guetta-Baranes T, Roca J, et al The role of IREB2 and transforming growth factor beta-1 genetic variants in COPD: a replication case-control study. BMC Med Genet. 2011; 12:24.
32. Pillai SG, Kong X, Edwards L.D., Cho MH, Anderson WH, Coxson HO, et al Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010; 182(12):1498-505.
33. Zhou H, Yang J, Li D., Xiao J, Wang B, Wang L., et al. Association of IREB2 and CHRNA3/5 polymorphisms with COPD and COPD-related phenotypes in a Chinese Han population. J Hum Genet. 2012; 57(11):738-46.
34. Pastinen T. Genome-wide allele-specific analysis: insights into regulatory variation. Nat Rev Genet. 2010; 11(8):533-8.
35. Needham M, Stockley RA Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax. 2004; 59(5):441-5.
36. Rahaghi FF, Sandhaus RA, Brantly M.L., Rouhani F., Campos MA, Strange C, et al. The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. COPD. 2012; 9(4):352-8.
37. Kim WJ, Wood AM, Barker A.F., Brantly ML, Campbell EJ, Eden E, et al Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. Respir Res. 2012; 13:16.
38. Ghio AJ, Soukup JM, Richards J.H., Fischer BM, Voynow JA, Schmechel DE. Deficiency of alpha-1-antitrypsin influences systemic iron homeostasis. Int J Chron Obstruct Pulmon Dis. 2013; 8:45-51.
39. Fischer BM, Domowicz DA, Zheng S, Carter J.L., McElvaney NG, Taggart C, et al. Neutrophil elastase increases airway epithelial nonheme iron levels. Clin Transl Sci. 2009; 2(5):333-9.
40. Amos CI, Wu X, Broderick P., Gorlov IP, Gu J, Eisen T, et al Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008; 40(5):616-22.
41. Spitz MR, Amos CI, Dong Q, Lin J., Wu X. The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst. 2008; 100(21):1552-6.
42. Hung RJ, McKay JD, Gaborieau V, Boffetta P., Hashibe M, Zaridze D, et al A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008; 452(7187):633-7.
43. Thorgeirsson TE, Geller F, Sulem P., Rafnar T, Wiste A, Magnusson K.P., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008; 452(7187):638-42.
44. Maffettone C, Chen G, Drozdov I., Ouzounis C, Pantapoulos K. Tumorigenic properties of iron regulatory protein 2 (IRP2) mediated by its specific 73-amino acids insert. PLoS One. 2010; 5(4):e10163.
45. Lui GY, Obeidy P, Ford S.J., Tselepis C., Sharp DM, Jansson PJ, et al. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol. 2013; 83(1):179-90.
46. Weinberg ED. Iron and susceptibility to infectious disease. Science. 1974; 184(4140):952-6.
47. Murray MJ, Murray AB, Murray M.B., Murray CJ. The adverse effect of iron repletion on the course of certain infections. Br Med J. 1978; 2(6145):1113-5.
48. De Voss J.J., Rutter K, Schroeder B.G., Su H., Zhu Y, Barry CE 3rd. The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc Natl Acad Sci U S A. 2000; 97(3):1252-7.
49. Gangaidzo IT, Moyo VM, Myundura E, Aggrey G., Murphree NL, Khumalo H, et al. Association of pulmonary tuberculosis with increased dietary iron. J Infect Dis. 2001; 184(7):936-9.
50. Miller MJ, Walz AJ, Zhu H, Wu C., Moraski G, Möllmann U, et al. Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria. J Am Chem Soc. 2011; 133(7):2076-9.
51. Tullius MV, Harmston CA, Owens C.P., Chim N., Morse RP, McMath LM, et al. Discovery and characterization of a unique mycobacterial heme acquisition system. Proc Natl Acad Sci U S A. 2011; 108(12):5051-6.
52. Grigoriu B, Jacobs F, Beuzen F., El Khoury R, Axler O, Brivet F.G., et al. Bronchoalveolar lavage cytological alveolar damage in patients with severe pneumonia. Crit Care. 2006; 10(1):R2.
53. Mason WJ, Skaar EP Assessing the contribution of heme-iron acquisition to Staphylococcus aureus pneumonia using computed tomography. PLoS One. 2009; 4(8):e6668.
54. Bachman MA, Lenio S, Schmidt L., Oyler JE, Weiser JN. Interaction of lipocalin 2, transferrin, and siderophores determines the replicative niche of Klebsiella pneumoniae during pneumonia. MBio, 2012. 3(6).
55. Ong CL, Potter AJ, Trappetti C, Walker M.J., Jennings MP, Paton JC, et al. Interplay between manganese and iron in pneumococcal pathogenesis: role of the orphan response regulator RitR. Infect Immun. 2013; 81(2):421-9.
56. Perkins-Balding D., Ratliff-Griffin M, Stojiljkovic I. Iron transport systems in Neisseria meningitides. Microbiol Mol Biol Rev. 2004; 68:154-71.
57. Alacantara J, Yu RH, Schryvers AB The region of human transferring involved in binding to bacterial transferring receptors is localized in the C-lobe. Mol Microbiol. 1993; 8:1135-43.
58. Larson JA, Howie HL, So M. Neisseria meningitides accelerates ferritin degradation in host epithelial cells to yield an essential iron source. Mol Microbiol. 2004; 53:807-20.
59. Barber MF, Elde NC Escape from bacterial iron piracy through rapid evolution of transferring. Science. 2014; 346:1362-66.
60. Ge R, Sun X. Iron acquisition and regulation systems in Streptococcus species. Metallomics. 2014; 6(5):996-1003.
61. Reid DW, Anderson GJ, Lamont IL Role of lung iron in determining the bacterial and host struggle in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2009; 297(5):L795-802.
62. Vasil ML, Ochsner UA The response of Pseudomonas aeruginosa to iron: genetics, biochemistry and virulence. Mol Microbiol. 1999; 34(3):399-413.
63. Chen X, Stewart PS Role of electrostatic interactions in cohesion of bacterial biofilms. Appl Microbiol Biotechnol. 2002; 59(6):718-20.
64. Britigan BE, Hayek MB, Doebbeling B.N., Fick RB Jnr. Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis. Infect Immun. 1993; 61(12):5049-55.
65. Hurley MN, Camara M, Smyth AR Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur Respir J. 2012; 40(4):1014-23.
66. Halwani M, Yebio B, Suntres Z.E., Alipour M., Azghani AO, Omri A. Coencapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J Antimicrob Chemother. 2008; 62(6):1291-7
67. Moreau-Marquis S., O'Toole GA, Stanton BA Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol. 2009; 41(3):305-13.
68. Sharkey RA, Donnelly SC, Connelly K.G., Robertso CE, Haslett C, Repine JE. Initial serum ferritin levels in patients with multiple trauma and the subsequent development of acute respiratory distress syndrome. Am J Respir Crit Care Med. 1999; 159(5 Pt 1):1506-9.
69. Ghio AJ, Carter JD, Richards J.H., Richer LD, Grissom CK, Elstad MR. Iron and iron-related proteins in the lower respiratory tract of patients with acute respiratory distress syndrome. Crit Care Med. 2003; 31(2):395-400.
70. Jenkins ZA, Hagar W, Bowlus C.L., Johansson HE, Harmatz P, Vichinsky EP, et al Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. Pediatr Hematol Oncol. 2007; 24(4):237-43.
71. Al Faraj A., Shaik AP, Shaik AS Effect of surface coating on the biocompatability and in vivo MRI detection of iron oxide nanoparticles after intrapulmonary administration. Nanotoxicology. 2015; 10:1-10.
72. Xue S, Zhang C, Yang Y., Zhang L, Cheng D, Zhang J., et al. 99mTc-Labeled iron oxide nanoparticles for dual-contrast (T1/T2) magnetic resonance and dual-modality imaging of tumor angiogenesis. J Biomed Nanotechnol. 2015; 11(6):1027-37.
73. Hamarat Sanlier S., Yasa M, Cihnioglu A.O., Abdulhayoglu M., Yilmaz H, Ak G. Development of gemcitabine-adsorbed magnetic gelatin nanoparticles for targeted drug delivery in lung cancer. Artif Cells Nanomed Biotechnol. 2015; 23:1-7.